Enveric Biosciences secures new U.S. patent allowance for next-generation, non-hallucinogenic mescaline derivatives in EVM401 series

Enveric Biosciences Inc. has received a U.S. patent allowance for a series of non-hallucinogenic mescaline derivatives under its EVM401 compound series, according to a recent filing with the U.S. Patent and Trademark Office [1]. The patent covers novel chemical modifications of mescaline, a naturally occurring psychedelic alkaloid, designed to retain therapeutic potential while eliminating hallucinogenic effects. This development aligns with the company’s ongoing research into psychedelic-inspired therapeutics for mental health conditions.

The EVM401 series is part of Enveric’s broader strategy to develop proprietary compounds with reduced regulatory and safety concerns compared to traditional psychedelics. The patent allowance represents a key milestone in the company’s intellectual property portfolio and could support future clinical development and commercialization efforts.

Enveric has not disclosed specific timelines for clinical trials or regulatory submissions related to the EVM401 series. The company’s stock has shown moderate volatility in recent months, reflecting broader market dynamics in the psychedelic therapeutics sector. Investors are likely to monitor further updates on preclinical data and potential partnerships as key indicators of progress.